FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APPROVAL									
	OMB Number:	3235-0287								
l	Estimated average burden									
l	hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					01 000		0(11) 0	1 1110		CITE O	Jilipally Act (31 10-10							
1. Name and Address of Reporting Person* <u>Riker Lauren Bullaro</u>						2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [PCRX]								5. Relationship of Reporting Person (Check all applicable) Director				rson(s) to I	
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 07/05/2023								X	belov	Officer (give title below)		Other (s	·
C/O PACIRA BIOSCIENCES, INC.															Senior Vice President, Finance				ce
5401 WEST KENNEDY BOULEVARD, SUITE 890					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
,																			
(Street)													Form filed by More than One Reportir Person					orung	
TAMPA	FL	3	3609		Rule 10b5-1(c) Transaction Indication														
						. T()DJ-	Ι (C) IIai	115a		licati	UII						
(City)	(City) (State) (Zip)					X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											tended		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y					Execut (ear) if any		emed tion Date, n/Day/Year)					s Acquired (A) of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership
										v	Amount	(A) oi (D)	Price		Transa	Reported Transaction(s) (Instr. 3 and 4)		. 4)	(Instr. 4)
Common	7/05/202	23				S ⁽¹⁾		643	D	\$38.9	1 ⁽²⁾ 22,687.335 ⁽³⁾		87.335 ⁽³⁾		D				
		Tab									osed of, convertib				Owne	ed		·	
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			n Date,	4. Transaction Code (Instr. 8)				3		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		Der Sec	Price of ivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.67 to \$39.40, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. Includes 643.335 shares of common stock acquired under the issuer's employee stock purchase plan in June 2023.

Remarks:

/s/ Kristen Williams, Attorney-in-Fact 07/07/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.